A. Boucly (Le Kremlin Bicètre, France), V. Foris (Graz, Austria)
Validation of EmPHasis-10 health-related quality of life assessment tool in Canadian patients with pulmonary hypertension.
A. McBride (Calgary, Canada), D. Helmersen (Calgary, Canada), N. Hirani (Calgary, Canada), M. Thakrar (Calgary, Canada), M. Kularatne (Calgary, Canada), J. Liu (Calgary, Canada), L. Harper (Calgary, Canada), H. Iqbal (Calgary, Canada), A. Naser (Calgary, Canada), R. Varughese (Calgary, Canada), J. Weatherald (Calgary, Canada), J. Weatherald (Edmonton, Canada)
|   |
Narrative medicine to investigate patients’ and caregivers’ experience of pulmonary arterialhypertension: the inspectio study
F. Baldi (Roma, Italy), L. Scelsi (Pavia, Italy), P. Ameri (Genova, Italy), G. Perna (Ancona, Italy), C. D'Agostino (Bari, Italy), P. Agostoni (Milano, Italy), N. Brunetti (Foggia, Italy), L. Dagna (Milano, Italy), G. Galgano (Acquaviva delle Fonti , Italy), A. Cappuccio (Milano, Italy), A. Fiorencis (Milano, Italy), F. Rucci (Cologno Monzese, Italy), R. Termini (Cologno Monzese, Italy), S. De Santis (Cologno Monzese, Italy)
| |
Correlation of emPHasis-10 with clinical tests: insights from the ASPIRE registry
S. Alabed (Sheffield, United Kingdom), K. Dwivedi (Sheffield, United Kingdom), C. Durrington (Sheffield, United Kingdom), F. Alandejani (Sheffield, United Kingdom), R. Lewis (Sheffield, United Kingdom), C. Eelliot (Sheffield, United Kingdom), A. Charalampopoulos (Sheffield, United Kingdom), R. Thompson (Sheffield, United Kingdom), A. Hameed (Sheffield, United Kingdom), A. Rothman (Sheffield, United Kingdom), I. Armstrong (Sheffield, United Kingdom), R. Condliffe (Sheffield, United Kingdom), A. Swift (Sheffield, United Kingdom), D. Kiely (Sheffield, United Kingdom)
| |
Health disparities and differences in health-care-utilization in patients with pulmonary arterial hypertension
D. Park (Hannover, Germany), T. Meltendorf (Hannover, Germany), K. Kahl (Hannover, Germany), J. Kamp (Hannover, Germany), M. Richter (Giessen, Germany), M. Hoeper (Hannover, Germany), K. Olsson (Hannover, Germany), J. Fuge (Hannover, Germany)
| |
Prognostic importance of centrilobular ground glass changes in patients with Idiopathic Pulmonary Arterial Hypertension
k. Dwivedi (Sheffield, United Kingdom), M. Sharkey (Sheffield, United Kingdom), R. Lewis (Sheffield, United Kingdom), M. Mamalakis (Sheffield, United Kingdom), S. Alabed (Sheffield, United Kingdom), S. Rajaram (Sheffield, United Kingdom), C. Hill (Sheffield, United Kingdom), D. Kiely (Sheffield, United Kingdom), J. Wild (Sheffield, United Kingdom), A. Swift (Sheffield, United Kingdom), R. Condliffe (Sheffield, United Kingdom)
| |
The significance of normal lung regions on quantitative CT in pulmonary hypertension
T. Okaya (Chiba, Japan), A. Shigeta (Chiba, Japan), N. Tanabe (Chiba, Japan), A. Nishiyama (Chiba, Japan), H. Yokota (Chiba, Japan), T. Sugiura (Chiba, Japan), S. Sakao (Chiba, Japan), K. Tatsumi (Chiba, Japan), T. Suzuki (Chiba, Japan)
| |
Different exercise tests with different risk assessment in PAH patients
A. Martinez Meñaca (Santander, Spain), R. Luna Lopez (Madrid, Spain), V. Mora Cuesta (Santander, Spain), T. Segura De La Cal (Madrid, Spain), A. Cruz Utrilla (Madrid, Spain), P. Alonso Lecue (Santander, Spain), J. Cifrian Martínez (Santander, Spain), P. Escribano Subias (Madrid, Spain)
| |
Limitations of functional class for predicting severity in pulmonary hypertension in Colombia
M. Pacheco (Pereire, Colombia), R. Conde (Bogotá, Colombia), A. Londoño (Medellín, Colombia), C. Velásquez (Medellín, Colombia), R. Gómez-Palau (Cali, Colombia), D. Tiga (Floridablanca, Colombia), J. De Luque (Bucaramanga, Colombia), A. Ramírez-Sarmiento (Bucaramanga, Colombia), M. Orozco-Levi (Floridablanca, Colombia)
| |
COMPERA score revised: better risk estimation to better tailor therapeutics in precapillary hypertension.
J. Brito (Lisbon, Portugal), P. Alves Da Silva (Lisbon, Portugal), S. Couto Pereira (Lisbon, Portugal), B. Garcia (Lisbon, Portugal), J. Rigueira (Lisbon, Portugal), T. Guimarães (Lisbon, Portugal), A. G Almeida (Lisbon, Portugal), F. J Pinto (Lisbon, Portugal), R. Placido (Lisbon, Portugal)
| |
Utility of the six minute walking test (6MWT) in the follow-up of patients with pulmonary arterial hypertension (PAH),is there a correlation between the distance walked and oxygen consumption?
I. Muñoz Ramirez (Cadiz, Spain), A. Marin Andreu (Cadiz, Spain), R. De Andrés David (Cadiz, Spain), A. Ais Daza (Cadiz, Spain), M. Morales Gonzalez (Cadiz, Spain), A. Arnedillo Muñoz (Cadiz, Spain)
| |
CMR assessed maladaptive right ventricular remodelling predicts treatment failure in pulmonary arterial hypertension
Z. Goh (Sheffield, United Kingdom), N. Balasubramanian (Sheffield, United Kingdom), S. Alabed (Sheffield, United Kingdom), K. Dwivedi (Sheffield, United Kingdom), Y. Shahin (Sheffield, United Kingdom), A. Mk Rothman (Sheffield, United Kingdom), P. Garg (Sheffield, United Kingdom), A. Lawrie (Sheffield, United Kingdom), D. Capener (Sheffield, United Kingdom), A. Thompson (Sheffield, United Kingdom), F. Alandejani (Sheffield, United Kingdom), J. M Wild (Sheffield, United Kingdom), C. S Johns (Sheffield, United Kingdom), R. A Lewis (Sheffield, United Kingdom), R. Gosling (Sheffield, United Kingdom), M. Sharkey (Sheffield, United Kingdom), R. Condliffe (Sheffield, United Kingdom), D. G Kiely (Sheffield, United Kingdom), A. J Swift (Sheffield, United Kingdom)
| |
Prognostic impact of hypochromic erythrocytes in patients with pulmonary arterial hypertension
V. Theobald (Heidelberg, Germany), P. Xanthouli (Heidelberg, Germany), N. Benjamin (Heidelberg, Germany), A. Marra (Naples, Italy), A. D’Agostino (Naples, Italy), B. Egenlauf (Heidelberg, Germany), M. Shaukat (Heidelberg, Germany), C. Ding (Heidelberg, Germany), A. Cittadini (Naples, Italy), E. Bossone (Naples, Italy), M. Kögler (Heidelberg, Germany), E. Grünig (Heidelberg, Germany), M. Muckenthaler (Heidelberg, Germany), C. Eichstaedt (Heidelberg, Germany)
| |
Risk stratification approaches perform differently in SSc-associated PAH in EUSTAR
H. Bjørkekjær (Kristiansand, Norway), C. Bruni (Zurich, Switzerland), P. Carreira (Madrid, Spain), P. Airò (Brescia, Italy), C. Simeón-Aznar (Barcelona, Spain), M. Truchetet (Bordeaux, France), A. Giollo (Verona, Italy), A. Balbir-Gurman (Haifa, Israel), M. Martin (Poitiers, France), C. Denton (London, United Kingdom), A. Gabrielli (Ancona, Italy), H. Fretheim (Oslo, Norway), I. Barua (Oslo, Norway), H. Bitter (Kristiansand, Norway), Ø. Midtvedt (Oslo, Norway), K. Broch (Oslo, Norway), A. Andreassen (Oslo, Norway), Y. Tanaka (Kitakyushu, Japan), G. Riemekasten (Lübeck, Germany), U. Müller-Ladner (Bad Nauheim, Germany), M. Matucci Cerinic (Milan, Italy), I. Castellví (Barcelona, Spain), E. Siegert (Berlin, Germany), E. Hachulla (Lille, France), O. Distler (Zurich, Switzerland), A. Hoffmann-Vold (Oslo, Norway)
| |
Pulmonary Arterial Hypertension risk assessment model using Bayesian Network analysis
C. Fauvel (Columbus, United States), Z. Liu (Columbus, United States), S. Lin (Columbus, United States), P. Correa-Jaque (Columbus, United States), A. Webb (Columbus, United States), R. Vanderpool (Columbus, United States), R. Benza (Columbus, United States)
| |
Oxygenated hemoglobin as prognostic marker among patients with systemic sclerosis screened for pulmonary hypertension
O. Gordjani (Heidelberg, Germany), P. Xanthouli (Heidelberg, Germany), C. Eichstaedt (Heidelberg, Germany), N. Benjamin (Heidelberg, Germany), F. Trudzinski (Heidelberg, Germany), B. Egenlauf (Heidelberg, Germany), S. Harutyunova (Heidelberg, Germany), A. Marra (Napoli, Italy), N. Milde (Heidelberg, Germany), C. Nagel (Heidelberg, Germany), N. Blank (Heidelberg, Germany), H. Lorenz (Heidelberg, Germany), E. Grünig (Heidelberg, Germany)
| |
Prediction of peak oxygen uptake from 6-minute walk test in pulmonary hypertension
P. Appenzeller (Zürich, Switzerland), F. Gautschi (Zürich, Switzerland), J. Müller (Zürich, Switzerland), M. Lichtblau (Zürich, Switzerland), S. Saxer (Zürich, Switzerland), S. Schneider (Zürich, Switzerland), E. Schwarz (Zürich, Switzerland), S. Ulrich (Zürich, Switzerland)
| |
Ventilatory limitation during cardiopulmonary exercise testing predicts survival in patients with pulmonary arterial hypertension with Eisenmenger physiology
C. Samaranayake (London, United Kingdom), R. Mcniven (London, United Kingdom), A. Kempny (London, United Kingdom), L. Price (London, United Kingdom), C. Harries (London, United Kingdom), M. Gatzoulis (London, United Kingdom), K. Dimopoulos (London, United Kingdom), S. Wort (London, United Kingdom), C. Mccabe (London, United Kingdom)
| |
D-Dimer predicts mortality in a real-life cohort of patients with indication for right heart catheterization
V. Foris (Medical University of Graz, Austria), F. Prüller (Graz, Austria), G. Kovacs (Graz, Austria), A. Avian (Graz, Austria), P. Douschan (Graz, Austria), T. Sassmann (Graz, Austria), K. Zeder (Graz, Austria), M. Herrmann (Graz, Austria), H. Olschewski (Graz, Austria)
| |
Lung transplantation in pulmonary arterial hypertension (PAH): survival analysis according to PAH risk
M. Zapata Ortega (Barcelona, Spain), E. Revilla López (Barcelona, Spain), B. Sáez Gimenez (Barcelona, Spain), C. Berastegui García (Barcelona, Spain), M. Arjona Peris (Barcelona, Spain), V. Monforte Torres (Barcelona, Spain), C. Bravo Masgoret (Barcelona, Spain), E. Domingo Ribas (Barcelona, Spain), M. López Meseguer (Barcelona, Spain)
| |
Elevated alveolar nitric oxide in precapillary pulmonary hypertension decreases after therapy
B. Csoma (Budapest, Hungary), G. Csósza (Budapest, Hungary), G. Szucs (Budapest, Hungary), V. Müller (Budapest, Hungary), K. Karlócai (Budapest, Hungary), Z. Lázár (Budapest, Hungary)
| |